XXB 750
Alternative Names: XXB-750Latest Information Update: 20 Feb 2024
At a glance
- Originator Novartis Pharmaceuticals
- Class Antihypertensives; Cardiovascular therapies; Heart failure therapies; Monoclonal antibodies
- Mechanism of Action Atrial natriuretic factor receptor A agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Heart failure; Resistant hypertension
Most Recent Events
- 18 Jan 2024 Novartis Pharmaceuticals completes a phase I trial in Heart failure (In adults , In elderly) in USA and Netherlands(NCT05328752) (EudraCT2021-006683-24)
- 12 Dec 2023 Phase-II clinical trials in Heart failure (Treatment-experienced) in USA (SC) (NCT06142383)
- 22 Nov 2023 Novartis pharmaceuticals plans a phase II trial for heart failure (Treatment-experienced) in unknown location (SC) (NCT06142383)